UBS Group
ENGN icon

UBS Group’s enGene Therapeutics ENGN Stock Holding History

UBS Group’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$881K Buy
509,087
+496,070
+3,811% +$2.02M ﹤0.01% 5834
2026
Q1 		$88.6K Buy
13,017
+11,420
+715% +$102K ﹤0.01% 7057
2025
Q4 		$14.4K Buy
+1,597
New +$12.8K ﹤0.01% 8004
2025
Q2 		– Sell
-1,200
Closed -$5.38K – 10387
2025
Q1 		$5.38K Hold
1,200
– – ﹤0.01% 9004
2024
Q4 		$7.98K Buy
+1,200
New +$9.32K ﹤0.01% 8436
2024
Q3 		– Sell
-3,370
Closed -$31.8K – 9632
2024
Q2 		$31.8K Buy
+3,370
New +$43.2K ﹤0.01% 7024
2024
Q1 		– Sell
-1,937
Closed -$17.9K – 9474
2023
Q4 		$17.9K Buy
+1,937
New +$17.1K ﹤0.01% 7173

Other funds holding ENGN

FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

UBS Group's ENGN Position: Q2 2026 in Review

UBS Group increased its enGene Therapeutics (ENGN) stake by 3,811% in Q2 2026, buying an estimated $2.02M and bringing the position to 509,087 shares worth $881K. The position accounts for ﹤0.01% of the portfolio, ranked #5834.

UBS Group first reported a position in ENGN in Q4 2023 and has held it in 7 quarters since. 60 funds tracked by Wall St. Rank hold ENGN as of Q2 2026.

  • UBS Group held 509,087 shares of enGene Therapeutics worth $881K as of Q2 2026.
  • UBS Group bought 496,070 enGene Therapeutics shares in Q2 2026, an estimated $2.02M.
  • enGene Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #5834 holding.
  • UBS Group first reported a position in enGene Therapeutics in Q4 2023 and has held it in 7 quarters since.
  • 60 funds tracked by Wall St. Rank held enGene Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.